The Clorox Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLX research report →
Range $83 – $127
Price Chart
About the company
The Clorox Company is a global manufacturer and marketer of both consumer and professional products, operating through four distinct segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness division offers a range of cleaning solutions, including laundry additives and home care items under brand names such as Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409. It also supplies professional cleaning and disinfecting products via the CloroxPro and Clorox Healthcare brands, alongside professional food service goods from Hidden Valley.
- CEO
- Linda J. Rendle
- IPO
- 1983
- Employees
- 9,200
- HQ
- Oakland, CA, US
Get TickerSpark's AI analysis on CLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.13B
- P/E
- 17.39
- Fwd P/E
- 14.48
- PEG
- -0.65
- P/S
- 1.51
- P/B
- 113.39
- EV/EBITDA
- 16.84
- Div Yield
- 5.93%
- Gross Margin
- 42.32%
- Op Margin
- 24.73%
- Net Margin
- 8.74%
- ROE
- -1893.55%
- ROIC
- 20.39%
Latest fiscal year · YoY change
- Revenue
- $6.72B-5.4%
- Gross Profit
- $2.84B-11.5%
- Op Income
- $1.66B
- Net Income
- $587.00M-27.5%
- EPS
- $4.82-26.5%
- OCF Growth
- -37.6%
- FCF Growth
- -46.8%
- 52W High
- $128.90
- 52W Low
- $81.60
- 50D MA
- $97.08
- 200D MA
- $101.92
- Beta
- 0.54
- RSI (14)
- 34
- Avg Volume
- 2.80M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Clorox said fiscal 2026 ended with sequential improvement and strong share gains in several businesses, while fiscal 2027 will still face elevated inflation and a muted category backdrop.· August 3, 2026
- Fiscal 2026 saw sequential improvement in consumption, share, and distribution, with June exit rates near flat and many businesses performing at or above expectations.
- Management expects fiscal 2027 organic sales to be flat to slightly up, with Q1 softer due to Kingsford timing and promotional noise before improvement later in the year.
- Inflation is expected to be above $200 million in fiscal 2027, driven by commodities plus logistics and supply-chain costs, with Brent assumed at about $90 per barrel.
- GOJO/Purell is already performing ahead of plan, was accretive in Q4, and is expected to be accretive to adjusted EPS next year.
- Clorox is leaning on targeted pricing, productivity, and brand reinvestment rather than broad-based price hikes; Glad is the main category called out for a more direct price increase.
Clorox did not state full-quarter revenue, EPS, or gross margin results in the prepared remarks and Q&A shown here. For fiscal 2027, management guided to organic sales that are flat to slightly up, reiterated a gross margin target around 42%, and said inflation should be above $200 million, more than double the historical $75 million to $100 million range. Luc Bellet also said free cash flow should remain in the company’s targeted 11% to 13% of sales range, SG&A should improve on a comparable basis, and interest expense is about $210 million. On the GOJO acquisition, Bellet said the business was accretive in Q4, expected to be accretive to adjusted EPS next fiscal year, and should run at mid-single-digit growth with potential to move to mid- to high-single digits as synergies build.
Linda Rendle framed fiscal 2026 as a year of urgent execution in a difficult environment marked by value-seeking consumers, competition, inflation, and macro uncertainty. Her tone was constructive and disciplined: she emphasized superiority, targeted reinvestment, and a stronger foundation for fiscal 2027, while saying the company is making sequential progress even if some businesses still need work. She also stressed that Clorox will continue to review the portfolio carefully, but there is nothing to announce yet.
Luc Bellet focused on inflation, margins, cash flow, and capital structure. He said fiscal 2027 inflation is expected to be above $200 million, with Brent crude assumed at about $90 per barrel and additional pressure from supplier costs, ocean freight, trucking, and logistics; he also noted the impact should be more pronounced in the first half. He said free cash flow should stay in the 11% to 13% of sales range, helped by working capital discipline, GOJO’s stable cash generation, and expected tax benefits. On SG&A, he said comparable productivity should exceed inflation next year, and on interest expense he said it is about $210 million.
Analysts pressed on the flat-to-slightly-up sales outlook, asking how much of the improvement comes from share gains versus easing timing issues. Management said Q1 is mainly a timing blip from Kingsford and some promotional shifts, and that the back half of the year should look more like fiscal 2026 trends, with share improvement continuing. Questions also focused on pricing, promotions, and whether the company has pricing power; management said pricing will be targeted rather than broad, with Glad getting a straight price increase and other categories using price pack architecture, promotions, and product improvements. Analysts also asked about GOJO, portfolio trimming, dividend policy, ERP savings, and the CEO search; management said GOJO is ahead of plan, the dividend remains supported, ERP benefits should ramp later this year and next, and the CEO search is progressing as expected.
The bull case from this call is that Clorox believes it has already moved past the worst operational issues and is seeing sequential share recovery in multiple businesses. Management pointed to Home Care’s eight straight quarters of share growth, strong Pro and International performance, a turnaround in Glad and Hidden Valley, and early progress in Litter and Fresh Step. They also said GOJO is performing ahead of plan and should add growth and cash flow, while ERP and Global Business Services should support efficiency gains later in fiscal 2027 and beyond.
The main risks are a still-muted consumer and category backdrop, above-normal inflation, and a soft Q1 due to timing issues in Kingsford and promotion. Management acknowledged that Litter remains a work in progress, Kingsford was hurt by weather and retailer merchandising choices, and fiscal 2027 gross margin recovery will be incomplete because inflation is concentrated in the first half. The company also said promotions remain elevated and that pricing must be carefully balanced so it does not damage share gains.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 120.92M
- Float Shares
- 120.01M
of shares held by institutions
1,130 13F filers
Buy/sell ratio 3.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CLX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert Ray CisnerosHouse · CA31 | Sell | May 15, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Buy | Dec 19, 25 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Sell | Nov 12, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 26, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 24, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Apr 11, 25 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Apr 29, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 20, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 3, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 15.68M | ▼ 54.68K |
| Blackrock, Inc. | 10.04M | ▼ 127.45K |
| State Street Corp | 8.43M | ▲ 177.95K |
| Vanguard Capital Management LLC | 7.90M | ▲ 45.95K |
| Invesco Ltd. | 6.01M | ▲ 1.15M |
| Vanguard Portfolio Management LLC | 5.80M | ▲ 15.36K |
| Geode Capital Management, LLC | 3.27M | ▲ 36.87K |
| Van Eck Associates Corp | 2.97M | ▼ 245.43K |
| Morgan Stanley | 2.25M | ▼ 469.23K |
| Millennium Management LLC | 2.07M | ▲ 1.38M |
| Ubs Group AG | 1.98M | ▲ 1.07M |
| Bank Of America Corp | 1.88M | ▲ 477.93K |
Held by 1,049 ETFs
Biggest fund positions in CLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Peck Laurene E | other | 2,192 |
| Sep 23, 26 | Marriner Kirsten | other | 12,389 |
| Sep 23, 26 | Hyder Chris T | other | 13,342 |
| Sep 23, 26 | Bellet Luc | other | 11,913 |
| Sep 23, 26 | Rendle Linda J | other | 50,988 |
| Sep 23, 26 | Barton Nina | other | 10,721 |
| Sep 23, 26 | Hilt Angela C | other | 11,436 |
| Jul 22, 26 | Barton Nina | other | 1,681 |
| Jul 15, 26 | Hyder Chris T | other | 277 |
| Jun 30, 26 | WILLIAMS CHRISTOPHER J | other | 288.139 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLX coverage
Recent articles, reports, and earnings notes.

Clorox (CLX): Execution Risk vs. Brand Strength
Clorox remains a durable branded-staples name, but flat revenue, higher debt, and a difficult ERP transition keep the stock in Hold territory. Household and International are improving, yet Fresh Step and Food remain key execution challenges.

Clorox (CLX): ERP Reset Masks a Fairly Priced Recovery
Clorox rebuilt profitability in fiscal 2025, but FY2026 guidance was cut sharply as ERP-related inventory drawdown hit sales and margins. The stock looks like a steady staples franchise in repair, with valuation close to fair and upside tied to execution.

The Clorox Company (CLX) drops 9% on profit outlook cut
The Clorox Company (CLX) drops sharply after cutting full-year profit guidance and warning that gross margins will weaken more than expected. The consumer staples name posted a mixed quarter, but investors are focusing on lower earnings power, margin pressure, and a tougher near-term outlook.
Want a deeper read on CLX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Clorox's Selloff May Not Be Over Yet (Rating Downgrade)
seekingalpha.com · Sep 24
HIDDEN VALLEY® INTRODUCES SPOOKY RANCH: THE ICONIC DRESSING TAKES ON A HAUNTING HUE FOR HALLOWEEN
prnewswire.com · Sep 24
Clorox Declares Regular Quarterly Dividend of $1.25 Per Share
gurufocus.com · Sep 23
Clorox Declares Regular Quarterly Dividend of $1.25 Per Share
prnewswire.com · Sep 23
Clorox: The Fundamentals Are Deteriorating - The Dividends Won't Save You
seekingalpha.com · Sep 22
Clorox vs. Kimberly-Clark: Which Household Staples Dividend Is Safer
247wallst.com · Sep 21
The Clorox Company $CLX Shares Bought by MAC Alpha Capital Management LP
defenseworld.net · Sep 21
These 6 Massive Dividend Yields May Be Too Good to Be True
247wallst.com · Sep 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.